Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Evipan
2. Hexenal
3. Hexobarbital, Sodium
4. Hexobarbitone
5. Sodium Hexobarbital
1. Hexobarbitone
2. Methylhexabital
3. Methexenyl
4. 56-29-1
5. Evipal
6. Evipan
7. Barbidorm
8. Cyclopan
9. Enhexymal
10. Noctivane
11. Sombucaps
12. Sombulex
13. Somnalert
14. Citopan
15. Methylhexabarbital
16. Cyclonal
17. Hexabarbital
18. Narcosan
19. Citodon
20. Dorico
21. Hexanastab Oral
22. Hexenal (barbiturate)
23. Esobarbitale
24. Hexobarbitalum
25. 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric Acid
26. N-methyl-5-cyclohexenyl-5-methylbarbituric Acid
27. 1,5-dimethyl-5-(1-cyclohexenyl)barbituric Acid
28. Hexobarbital Ciii
29. 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
30. Nsc 71929
31. 5-(1-cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
32. 5-(1-cyclohexenyl-1)-1-methyl-5-methylbarbituric Acid
33. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-
34. Nsc-71929
35. Al8z8k3p6s
36. Barbituric Acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-
37. Chebi:5706
38. Enhexymalum
39. Hexobarbitonum
40. 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1h,3h,5h)-trione
41. Ncgc00159430-02
42. Ncgc00159430-03
43. Ncgc00159430-04
44. Hexobarbital (van)
45. Esobarbitale [dcit]
46. Esobarbitale [italian]
47. Dsstox_cid_3122
48. Dsstox_rid_76882
49. Dsstox_gsid_23122
50. Hexobarbitalum [inn-latin]
51. 5-cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione
52. 5-(.delta.-1,2-cyclohexenyl)-5-methyl-n-methyl-barbitursaeure
53. 5-cyclohexenyl-1,5-dimethylpyrimidine-2,4,6(1h,3h,5h)-trione
54. 5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
55. Cas-56-29-1
56. Einecs 200-264-9
57. Hexobarbital (jan/inn)
58. Unii-al8z8k3p6s
59. Ai3-61892
60. Hexobarbital [usp:inn:ban:jan]
61. 5-(delta-1,2-cyclohexenyl)-5-methyl-n-methyl-barbitursaeure [german]
62. (+/-)-hexobarbital
63. 5-(delta-1,2-cyclohexenyl)-5-methyl-n-methyl-barbitursaeure
64. Hexobarbital [mi]
65. Hexobarbital [inn]
66. Hexobarbital [jan]
67. Barbituric Acid,5-dimethyl-
68. Chembl7728
69. Hexobarbital [vandf]
70. Oprea1_350917
71. Schembl29821
72. Hexobarbital [mart.]
73. Mls001143909
74. Hexobarbital [who-dd]
75. Dtxsid9023122
76. Hexobarbital [ep Impurity]
77. Hms2272k03
78. Nsc71929
79. Hexobarbital 1.0 Mg/ml In Methanol
80. Tox21_111661
81. Tox21_111662
82. Stk696034
83. 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1h,3h,5h)-trione
84. 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1h,5h)-dione
85. Akos000355976
86. Akos016347605
87. Tox21_111661_1
88. Db01355
89. Ac-16076
90. Smr000473348
91. Db-052887
92. Wln: T6vmvnv Fhj D1 F1 F- Al6utj
93. D01071
94. 5-(cyclohexen-1-yl)-1,5-dimethylbarbitursaeure
95. 5-(cyclohexen-1-yl)-1,5-dimethylbarbituric Acid
96. Q421183
97. 5-(cyclohex-1-enyl)-1,5-dimethyl-barbituric Acid
98. Hexobarbital, United States Pharmacopeia (usp) Reference Standard
99. 2,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-
100. 5-(1-cyclohexenyl)-1,5-dimethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
101. Hexobarbital Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 236.27 g/mol |
|---|---|
| Molecular Formula | C12H16N2O3 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 236.11609238 g/mol |
| Monoisotopic Mass | 236.11609238 g/mol |
| Topological Polar Surface Area | 66.5 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 428 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was subsequently used in the 1940s and 1950s as an anesthetic for surgery. Furthermore, the agent also demonstrates a fairly quick onset of action that also possesses a short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days.
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
N - Nervous system
N01 - Anesthetics
N01A - Anesthetics, general
N01AF - Barbiturates, plain
N01AF02 - Hexobarbital
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CA - Barbiturates, plain
N05CA16 - Hexobarbital
Hepatic.
Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
A Hexobarbital manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hexobarbital, including repackagers and relabelers. The FDA regulates Hexobarbital manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hexobarbital API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Hexobarbital supplier is an individual or a company that provides Hexobarbital active pharmaceutical ingredient (API) or Hexobarbital finished formulations upon request. The Hexobarbital suppliers may include Hexobarbital API manufacturers, exporters, distributors and traders.
click here to find a list of Hexobarbital suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hexobarbital DMF (Drug Master File) is a document detailing the whole manufacturing process of Hexobarbital active pharmaceutical ingredient (API) in detail. Different forms of Hexobarbital DMFs exist exist since differing nations have different regulations, such as Hexobarbital USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hexobarbital DMF submitted to regulatory agencies in the US is known as a USDMF. Hexobarbital USDMF includes data on Hexobarbital's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hexobarbital USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hexobarbital suppliers with USDMF on PharmaCompass.
Hexobarbital Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hexobarbital GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hexobarbital GMP manufacturer or Hexobarbital GMP API supplier for your needs.
A Hexobarbital CoA (Certificate of Analysis) is a formal document that attests to Hexobarbital's compliance with Hexobarbital specifications and serves as a tool for batch-level quality control.
Hexobarbital CoA mostly includes findings from lab analyses of a specific batch. For each Hexobarbital CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hexobarbital may be tested according to a variety of international standards, such as European Pharmacopoeia (Hexobarbital EP), Hexobarbital JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hexobarbital USP).
LOOKING FOR A SUPPLIER?
